다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Cancer letters, v.451, 2019년, pp.11 - 22
Shimomura, Iwao (Division of Molecular and Cellular Medicine, National Cancer Center Research Institute) , Yokoi, Akira (Division of Molecular and Cellular Medicine, National Cancer Center Research Institute) , Kohama, Isaku (Division of Molecular and Cellular Medicine, National Cancer Center Research Institute) , Kumazaki, Minami (Division of Molecular and Cellular Medicine, National Cancer Center Research Institute) , Tada, Yuji (Department of Respirology, Graduate School of Medicine, Chiba University) , Tatsumi, Koichiro (Department of Respirology, Graduate School of Medicine, Chiba University) , Ochiya, Takahiro (Division of Molecular and Cellular Medicine, National Cancer Center Research Institute) , Yamamoto, Yusuke (Division of Molecular and Cellular Medicine, National Cancer Center Research Institute)
AI-Helper
Abstract KRAS is one of the most frequently mutated oncogenes in human non-small cell lung cancer (NSCLC). Mutations in KRAS are detected in 30% of NSCLC cases, with most of them occurring in codons 12 and 13 and less commonly in others. Despite intense efforts to develop drugs targeting mutant KRA...
CA A Cancer J. Clin. Torre 65 87 2015 10.3322/caac.21262 Global cancer statistics, 2012
N. Engl. J. Med. Schiller 346 92 2002 10.1056/NEJMoa011954 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
Adv. Exp. Med. Biol. Torre 893 1 2016 10.1007/978-3-319-24223-1_1 Lung cancer statistics
Respir. Med. Stella 106 173 2012 10.1016/j.rmed.2011.10.015 Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
Science (New York, N.Y.) Paez 304 1497 2004 10.1126/science.1099314 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
Nature Soda 448 561 2007 10.1038/nature05945 Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
N. Engl. J. Med. Lynch 350 2129 2004 10.1056/NEJMoa040938 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
N. Engl. J. Med. Solomon 371 2167 2014 10.1056/NEJMoa1408440 First-line crizotinib versus chemotherapy in ALK-positive lung cancer
Nature Network 511 543 2014 10.1038/nature13385 Comprehensive molecular profiling of lung adenocarcinoma
Clin. Cancer Res.: Off. J. Am. Assoc. Canc. Res. Dogan 18 6169 2012 10.1158/1078-0432.CCR-11-3265 Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
Cell Imielinski 150 1107 2012 10.1016/j.cell.2012.08.029 Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
Nat. Rev. Canc. Downward 3 11 2003 10.1038/nrc969 Targeting RAS signalling pathways in cancer therapy
Cancer Cell A G Stephen 25 272 2014 10.1016/j.ccr.2014.02.017 Dragging ras back in the ring
Cell Luo 137 835 2009 10.1016/j.cell.2009.05.006 A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
Nat. Rev. Canc. Malumbres 3 459 2003 10.1038/nrc1097 RAS oncogenes: the first 30 years
Cancer Cell Tuveson 5 375 2004 10.1016/S1535-6108(04)00085-6 Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects
J. Natl. Cancer Inst. Ihle 104 228 2012 10.1093/jnci/djr523 Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome
Oncogene Roberts 26 3291 2007 10.1038/sj.onc.1210422 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Nat. Rev. Drug Discov. Liu 8 627 2009 10.1038/nrd2926 Targeting the phosphoinositide 3-kinase pathway in cancer
Nat. Rev. Canc. Zhang 9 28 2009 10.1038/nrc2559 Targeting cancer with small molecule kinase inhibitors
Clin. Pharmacol. Therapeut. Swinney 93 299 2013 10.1038/clpt.2012.236 Phenotypic vs. target-based drug discovery for first-in-class medicines
Nat. Rev. Drug Discov. Jones 16 285 2017 10.1038/nrd.2016.244 Applications of chemogenomic library screening in drug discovery
Cancer Res. Chou 70 440 2010 10.1158/0008-5472.CAN-09-1947 Drug combination studies and their synergy quantification using the Chou-Talalay method
Nat. Rev. Drug Discov. Cox 13 828 2014 10.1038/nrd4389 Drugging the undruggable RAS: mission possible?
Cell Scholl 137 821 2009 10.1016/j.cell.2009.03.017 Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
Cancer Cell Puyol 18 63 2010 10.1016/j.ccr.2010.05.025 A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma
Cold Spring Harbor Perspect. Med. Holderfield 8 2018 10.1101/cshperspect.a031864 Efforts to develop KRAS inhibitors
Bioorg. Med. Chem. Bansal 20 6208 2012 10.1016/j.bmc.2012.09.013 The therapeutic journey of benzimidazoles: a review
Parasitol. today (Personal ed.) Campbell 6 130 1990 10.1016/0169-4758(90)90231-R Benzimidazoles: veterinary uses
Bioorg. Med. Chem. Lett Wang 24 4250 2014 10.1016/j.bmcl.2014.07.035 New benzimidazole-2-urea derivates as tubulin inhibitors
Mol. Canc. Therapeut. Sasaki 1 1201 2002 The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells
Bioorg. Med. Chem. Lett White 14 2433 2004 10.1016/j.bmcl.2004.03.017 Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors
J. Med. Chem. Kim 39 992 1996 10.1021/jm950412w Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity
Bioorg. Med. Chem. Li 19 4529 2011 10.1016/j.bmc.2011.06.022 Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors
Anti Cancer Agents Med. Chem. Yadav 16 1403 2016 10.2174/1871520616666151103113412 Perspectives of benzimidazole derivatives as anticancer agents in the new era
Curr. Med. Chem. Garuti 21 2284 2014 10.2174/0929867321666140217105714 Benzimidazole derivatives as kinase inhibitors
Mol. Cell. Biochem. Kubinski 426 195 2017 10.1007/s11010-016-2892-x Benzimidazole inhibitors of protein kinase CK2 potently inhibit the activity of atypical protein kinase Rio1
J. Med. Chem. Sonawane 59 8667 2016 10.1021/acs.jmedchem.6b00150 Cyclin dependent kinase 9 inhibitors for cancer therapy
Cell Death Dis. Chu 6 2015 10.1038/cddis.2015.25 A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells
Clin. Cancer Res.: Off. J. Am. Assoc. Canc. Res. McCormick 21 1797 2015 10.1158/1078-0432.CCR-14-2662 KRAS as a therapeutic target
Nature Barbie 462 108 2009 10.1038/nature08460 Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Nat. Med. Lito 19 1401 2013 10.1038/nm.3392 Tumor adaptation and resistance to RAF inhibitors
Cancer Cell Lito 25 697 2014 10.1016/j.ccr.2014.03.011 Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors
Cancer Cell Castellano 24 617 2013 10.1016/j.ccr.2013.09.012 Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance
Nature Manchado 534 647 2016 10.1038/nature18600 A combinatorial strategy for treating KRAS-mutant lung cancer
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.